$CLVS Q2 ER will determine where the price will be heading for next 6 months. Big funds such as State Street seems to be more confident than many of the retail investors. If Covid doesn't impact rubraca for Ovarian but instead drives more patients to switch from intravenous to oral, plus higher take up from Europe, we will see a good run up to SP. Prostate sales will be the final icing on the cake.
  • 9